Hamamatsu - Sensorhersteller // Wettbewerber von Silicon Sensor - 500 Beiträge pro Seite

[R-BgO]

10.06.2009 18:04
Aperio Files Patent Infringement Lawsuit Against Olympus America, Hamamatsu Corporation and Hamamatsu Photonics

Global Digital Pathology Leader Enforces Patents Covering Use of Line-Scan Cameras Including TDI Arrays and Prefocus Technology in Digital Pathology Systems

Aperio Technologies, Inc., (Aperio), a global leader in digital pathology for the healthcare and life sciences industry, announced today that it has filed suit for patent infringement against Olympus America, Inc., Hamamatsu Corporation and Hamamatsu Photonics KK (together, Hamamatsu). The lawsuit, filed in the United States District Court for the District of Delaware, alleges that Hamamatsu’s NanoZoomer digital pathology system distributed by Olympus America infringes three United States patents issued to Aperio.

”Aperio has invested significant resources in research and development to create the most technologically advanced slide scanners and software systems available today,” said Dirk Soenksen, CEO of Aperio. ”Our ultra-fast line-scanning technology has contributed significantly to the creation and growth of the digital pathology market. Additionally, our innovative approaches to image acquisition and processing, including our patented prefocus technology, are poised to unlock a plethora of commercial opportunities. We have an obligation to our shareholders to protect our intellectual property. After years of repeated and unsuccessful attempts to engage Olympus America and Hamamatsu in discussions about our intellectual property, we are taking legal action to defend that property from further infringement.”

Aperio’s complaint accuses Olympus America and Hamamatsu of infringing three Aperio patents relating to digital pathology. The three patents asserted in the lawsuit are: United States Patent No. 6,917,696 entitled ”Fully Automatic Rapid Microscope Slide Scanner,” United States Patent No. 7,457,446 entitled ”Fully Automatic Rapid Microscope Slide Scanner,” and United States Patent No. 7,518,652 entitled ”Method and Apparatus for Prefocus in a Linear Array Based Slide Scanner.”

Since its inception in 1999, Aperio has built a formidable patent position to protect the valuable inventions resulting from its significant investment in research and development. Aperio’s intellectual property portfolio now comprises more than 55 issued or pending patents covering slide scanning, data management, and image viewing and analysis.

Aperio has retained Quinn Emanuel Urquhart Oliver&Hedges, LLP, the premier business litigation firm in the United States, as counsel in this action.

About Aperio

Aperio is digitizing pathology. We provide systems and services for digital pathology, which is an environment for the management and interpretation of pathology information that originates with the digitization of a glass slide. Aperio’s award-winning ScanScope® slide scanning systems and Spectrum™ digital pathology information management software improve the efficiency and quality of pathology services for pathologists and other professionals. Applications include education, remote viewing, archival and retrieval, basic research and image analysis. Aperio’s products are FDA cleared for specific clinical applications, and are intended for research and education use for other applications. For clearance updates and more information, please visit www.aperio.com.

[R-BgO]

1. Comments on Consolidated Performance
(1) Summary of Consolidated Performance for the Second Quarter of this Fiscal Year
(2) Sales by Segment
a. Opto-Electronic Devices:
b. Imaging and Measurement Instruments:
c. Others:
(3) Sales by Location of companies
Theincometaxes of JPY943millionis includedintheincometax refunds inprevious years of JPY818million for a
compensatingadjustment ontransferpricingforthetransfersof productsbetweenHamamatsuPhotonicsK.K. andHamamatsu
PhotonicsDeutschlandGmbHfor thesixyearsfromtheyear endedSeptember 30, 1999throughtheyear endedSeptember
30, 2004andtheincometaxesinpreviousyearsof JPY527millionforit underAdvancedPricingAgreement forthefouryears
from the year ended September 30, 2005 through the year ended September 30, 2008.
For thefirst sixmonthsof thisfiscal year, theJapaneseeconomycontinuedtosuffer fromasharpdownturncausedbythe
global financial crisis and the sharp appreciation of the yen. Meanwhile, corporate profits and employments continued to shrink.
Against thisbackground,weundertooktoboostourrevenueandincomebyintensivesalesactivitiesandstreamliningoperating
expenses. Incontrast tothegrimfinancial news, wecommunicatedapositivemessagethat our fundamental researchand
product development areprogressingsteadily. “PHOTONFAIR2009”wasacomprehensiveexhibitionof our technology,
presentedbyHamamatsuPhotonicsK.K. It washeldinHamamatsuCity, JapaninFebruary2009, inspiteof theglobal
economic downturn.
Asaresult of theabovefactors, weclosedthesecondquarterwithnet salesof JPY38,383million, downbyJPY11,091million
(22.4%), operatingincomeof JPY3,227million, downbyJPY7,553million(70.1%)andordinaryincomeof JPY3,592million,
downbyJPY7,862million(68.6%)overoneyearbeforerespectively. Net incomeresultedinJPY1,234million, downbyJPY
5,878 million (82.6%).
Photomultiplier Tube sales inthemedical fieldsuchas gammacameraandPositronEmissionTomography(PET)
increasedsteadilybecauseof theirhighperformance. Ontheotherhand, salesinthefieldof emissionanalysesdecreased
suddenly, although last year, their sales were up, due to an increase of steel demand.
Inthe Light SourcesandImagingDevices, thesalesof X-rayScintillators, that convert X-raysintooptical imagesfor
dental andbreast imaging, increasedsteadily. However, salesof MicrofocusX-raysourcesfor non-destructiveinspection
systemsandUVSpot Light Sourcefor UVcurebondingdecreasedsharplyduetoadjustment of productionandreduction
of capital investment mainly in Japan.
Sales of high-performance digital cameras used in fundamental research for the bio-technology increased steadily.
However, SemiconductorFailureAnalysisSystemssalesdroppedrapidlyduetoreductionof capital investment inthefield
of semiconductors. In addition, sales of drug screening systems (FDSS) for research in pharmaceutical were down.
Net salesfor thissector resultedinJPY5,783million, downby24.3%andoperatingincomeof JPY497million, downby
60.7% from one year before.
In Japan, export sales of Photomultiplier Tubes in medical applications, such as nuclear medical imaging systems,
includinggammacamerasandPETincreasedsteadilycenteredmainlyintheU.S. market, Likewise, SiliconPhotodiodes
also increased again predominately in the U.S. market. Meanwhile export sales of X-ray Image Sensors for dental
instrumentationsoldmainlytoEuropeandAsiaalongwithexport salesof PhotoICsusedincommunicationnetwork
applicationsfor theautomobileindustrytoEuropedecreased. Inaddition, domesticsalesandexport salestoAsiaof the
UVSpot Light Sourcefor UVcurebondingandsalesof industrial Semiconductor FailureAnalysisSystemsdecreased.
Total salesinJapanwereJPY34,140million, downby21.0%andoperatingprofitsJPY6,578million, downby50.5%
compared with one year before respectively.
Net salesfor thesecondquarter of thisfiscal year wereJPY297million, downby12.5%over last year andoperating
income was JPY 0 million (2nd Quarter of FY 2008 was JPY 43 million operating loss).
In NorthAmerica, sales of Photomultiplier Tubes in the medical field for PETand gamma cameras, and Silicon
Photodiodesincreasedsteadily. However, salesof ImagingandMeasurement Instrumentsdecreased; anappreciationof
theyencausedthedecreasedsales. Thetotal salesfortheregionwereJPY10,862million, downby11.6%andoperating
profit JPY 149 million, down by 13.2% over last year respectively.
Europeexperiencedadecreaseinsalesof ImageSensorsfordental X-rayimagingandPhotoICsforautomotivenetwork
applications. Inaddition, astrongeryenledtoadecreaseinsales. Total saleswereJPY9,477million, downby22.0%and
operating profit JPY 843 million, down by 50.9% over last year respectively.
InOtherRegionsmostlyrepresentedbyChina, net saleswereJPY1,402million; upby29.4%andoperatingprofit JPY
249 million, up by 29.0%.
IntheOpto-semiconductorsector, salesof SiliconPhotodiodesfor themedical fieldcontinuedtogrowduetoincreased
performanceandfunctionsasaresult of utilizingour ownMicro-Electro-Mechanical Systems(MEMS) technologyintheir
designandoperation. However, salesof ImageSensorsfor dental applicationswhichhadbeenincreasingrapidlyfor the
last fewyears weredown, duetoanadjustment of inventories at thecustomers’side. Sales of PhotoICs usedin
communication network applications for the European automobile industry also grew at a sluggish pace
Intotal Opto-ElectronicDevicesclosedthesecondquarterwithJPY32,694million,downby21.9%andoperatingincomeof
JPY 7,636 million, down by 46.8% from one year previous.

[boygeorge]

Übersetz mal

[GOTOX]

NIEMAND WIRD ES WAGEN UNSERE SILICON SENSOR ZU SCHLAGEN !

[GOTOX]

Antwort auf Beitrag Nr.: 37.368.103 von boygeorge am 10.06.09 22:23:03

Welche Sprache willst Du denn?

[R-BgO]

Antwort auf Beitrag Nr.: 37.368.120 von GOTOX am 10.06.09 22:24:50

Hui, soviel Resonanz hatte ich definitiv nicht erwartet!

Habe selber 'ne große Ladung SIS und will nur mal ein Auge auf die hier mitwerfen, weil sie einer der zwei Namen sind, die Dr. Giering immer wieder erwähnt.


Sorry wegen des Layouts aus den HJ-Zahlen; kommt bei copy-paste manchmal so raus.

[R-BgO]

Hamamatsu launches InGaAs PIN photodiodes
A Hamamatsu Photonics UK product story
More from this company More from this category
Edited by the Electronicstalk editorial team May 21, 2009

Hamamatsu Photonics has introduced the G10899 Series of InGaAs PIN photodiodes, featuring a very wide spectral response range of 0.5 to 1.7um.

Standard InGaAs PIN photodiodes only offer a useful response range from 0.9 to 1.7um, with silicon photodiodes being used to cover from 400nm to 1.1um.

The G10899 can provide the end user with the ability to implement only one detector, where in the past they might have needed two.

This feature lends itself well to the optical communications field, since the G10899 has high sensitivity at three of the commonly used wavelengths for optical communications (850nm, 1,310nm and 1,550nm), whereas a standard InGaAs detector would have very low response at 850nm.

The G10899 Series is available in three standard active-area sizes, 1, 2 and 3mm, with the 1mm device operating at bandwidths up to 45MHz and with a very low dark current, typically 1nA.

In the optical communications sector, the G10899 Series is most useful for use in optical power meters, OTDRs, tunable laser diode monitors and free space communications, as well as other network monitoring applications.

The properties of this range of devices also make them suitable for spectral analysis, industrial inspection and temperature sensing applications.

[boygeorge]

Antwort auf Beitrag Nr.: 37.368.135 von GOTOX am 10.06.09 22:26:33

türkisch oder deutsch, sei so gut

[R-BgO]

10.06.2009 18:04
Aperio Files Patent Infringement Lawsuit Against Olympus America, Hamamatsu Corporation and Hamamatsu Photonics

Global Digital Pathology Leader Enforces Patents Covering Use of Line-Scan Cameras Including TDI Arrays and Prefocus Technology in Digital Pathology Systems

Aperio Technologies, Inc., (Aperio), a global leader in digital pathology for the healthcare and life sciences industry, announced today that it has filed suit for patent infringement against Olympus America, Inc., Hamamatsu Corporation and Hamamatsu Photonics KK (together, Hamamatsu). The lawsuit, filed in the United States District Court for the District of Delaware, alleges that Hamamatsu’s NanoZoomer digital pathology system distributed by Olympus America infringes three United States patents issued to Aperio.

”Aperio has invested significant resources in research and development to create the most technologically advanced slide scanners and software systems available today,” said Dirk Soenksen, CEO of Aperio. ”Our ultra-fast line-scanning technology has contributed significantly to the creation and growth of the digital pathology market. Additionally, our innovative approaches to image acquisition and processing, including our patented prefocus technology, are poised to unlock a plethora of commercial opportunities. We have an obligation to our shareholders to protect our intellectual property. After years of repeated and unsuccessful attempts to engage Olympus America and Hamamatsu in discussions about our intellectual property, we are taking legal action to defend that property from further infringement.”

Aperio’s complaint accuses Olympus America and Hamamatsu of infringing three Aperio patents relating to digital pathology. The three patents asserted in the lawsuit are: United States Patent No. 6,917,696 entitled ”Fully Automatic Rapid Microscope Slide Scanner,” United States Patent No. 7,457,446 entitled ”Fully Automatic Rapid Microscope Slide Scanner,” and United States Patent No. 7,518,652 entitled ”Method and Apparatus for Prefocus in a Linear Array Based Slide Scanner.”

Since its inception in 1999, Aperio has built a formidable patent position to protect the valuable inventions resulting from its significant investment in research and development. Aperio’s intellectual property portfolio now comprises more than 55 issued or pending patents covering slide scanning, data management, and image viewing and analysis.

Aperio has retained Quinn Emanuel Urquhart Oliver&Hedges, LLP, the premier business litigation firm in the United States, as counsel in this action.

About Aperio

Aperio is digitizing pathology. We provide systems and services for digital pathology, which is an environment for the management and interpretation of pathology information that originates with the digitization of a glass slide. Aperio’s award-winning ScanScope® slide scanning systems and Spectrum™ digital pathology information management software improve the efficiency and quality of pathology services for pathologists and other professionals. Applications include education, remote viewing, archival and retrieval, basic research and image analysis. Aperio’s products are FDA cleared for specific clinical applications, and are intended for research and education use for other applications. For clearance updates and more information, please visit www.aperio.com.

[R-BgO]

Hamamatsu Corporation has announced the release of its next-generation slide scanners, the NanoZoomer 2.0 series. Operating at nearly twice the speed of the original series, the NanoZoomer 2.0 converts a 20 mm x 20 mm area on a glass slide into a 1.9-gigapixel color image in as little as 1 minute 40 seconds. The resulting "virtual slides" can be conveniently viewed on a computer monitor, shared across computer networks, used for software-aided image analysis in a variety of research applications, and preserved in digital archives. Because the captured image contains nearly two billion pixels, users can magnify specific areas of the image to inspect fine details. The NanoZoomer 2.0 also enables users capture and view multiple focal planes in thick samples (Z-stack scanning).

The NanoZoomer 2.0 is available in two types. The flagship model, NanoZoomer 2.0-HT, is a fully automated high-throughput scanner that scans up to 210 slides continuously. It is ideal for overnight scanning of large batches of samples. A more compact model, the NanoZoomer 2.0-RS, provides the same high speed and high resolution as the HT model for a smaller number of slides. The RS model handles up to 6 standard slides (76 mm x 26 mm) or 2 double-sized slides (76 mm x 52 mm). Both the HT and RS models can be fitted with an optional fluorescence imaging unit.

The NanoZoomer 2.0 series will be introduced to the public at the CAP '09 meeting in Washington, D.C. from October 11 to 13, 2009. It will be on display at Olympus America's exhibit (booth 417). Olympus America is a distributor of Hamamatsu's NanoZoomer 2.0 series in North America. Information on purchasing and upgrade options can be obtained from Olympus America by calling 1-800-446-5967 1-800-446-5967 . Answers to frequently asked questions are available on their website: http://www.olympusamerica.com/seg_section/seg_askolympus.asp

Full technical specifications of the NanoZoomer 2.0 series can also be downloaded from Hamamatsu's website: http://www.nanozoomer.com/

Posted October 7th, 2009

[R-BgO]

Hamamatsu Photonics K.K. Raises Consolidated Mid-year and Full-year Outlook for FY Ended September 2009
Monday, 14 Dec 2009 01:30am EST

Hamamatsu Photonics K.K. announced that it has raised its consolidated mid-year outlook for revenue from JPY 36,400 million to JPY 39,900 million, operating profit from JPY 1,100 million to JPY 3,300 million, ordinary profit from JPY 1,200 million to JPY 3,400 million, net profit from JPY 500 million to JPY 2,100 million and earning per share from JPY 6.22 to JPY 26.12 for the fiscal year ended September 2009. The Company also has raised its consolidated full-year outlook for revenue from JPY 74,800 million to JPY 78,300 million, operating profit from JPY 3,500 million to JPY 5,700 million, ordinary profit from JPY 3,700 million to JPY 5,900 million, net profit from JPY 2,200 million to JPY 3,800 million and earning per share from JPY 27.36 to JPY 47.27 for the fiscal year ended September 2009. This is due to the more-than-expected sales.

[R-BgO]

Hamamatsu Photonics K.K. Raises Interim Dividend Forecast for FY Ending September 2010
Friday, 19 Mar 2010 02:31am EDT

Hamamatsu Photonics K.K. announced that it has raised its interim divided forecast from JPY 15,00 per share, which was announced on November 9, 2009, to JPY 18.00 per share, and reaffirmed its year-end dividend forecast of JPY 18.00 per share for the fiscal year ending September 2010.

[R-BgO]

läuft gut da:


Hamamatsu Photonics K.K. Raises Consolidated Mid-year and Full-year Outlook for FY Ending September 2010
Friday, 19 Mar 2010 02:30am EDT

Hamamatsu Photonics K.K. announced that it has raised its consolidated mid-year outlook for revenue from JPY 39,900 million to JPY 42,500 million, operating profit from JPY 3,300 million to JPY 6,200 million, ordinary profit from JPY 3,400 million to JPY 6,400 million, net profit from JPY 2,100 million to JPY 4,500 million and earning per share from JPY 26.12 to JPY 55.97 for the fiscal year ending September 2010. The Company has raised its consolidated full-year outlook for revenue from JPY 78,300 million to JPY 83,300 million, operating profit from JPY 5,700 million to JPY 10,500 million, ordinary profit from JPY 5,900 million to JPY 10,800 million, net profit from JPY 3,800 million to JPY 7,700 million and earning per share from JPY 47.27 to JPY 95.78 for the fiscal year ending September 2010. This is due to the more-than-expected sales.

[R-BgO]

Qualitative Information Related to Consolidated Performance for the first quarter of this Fiscal Year
(1) Consolidated Operating Results
Unemployment was high and the recovery of business from the effects of the “great recession” was anemic during the first quarter of this fiscal year. This was true despite the expected increase in personal consumption brought about by the improvement in the overseas economic situation resulting from economic stimulus measures. Against this background, our group strove to develop competitive products utilizing our own photonics technologies. Moreover, we undertook to boost our revenue and income by intensive sales activities and streamlining operating expenses.
As a result of the above factors, we closed the first quarter with net sales of JPY 24,684 million, up by JPY 5,192 million (26.6%), operating income of JPY 4,947 million, up by JPY 3,146 million (174.8%) and ordinary income of JPY 5,029 million, up by JPY 3,276 million (186.9%) over one year before respectively. Net income resulted in JPY 2,977 million, up by JPY 1,768 million (146.3%).
Performance by segment was as follows;
(Electron Tube) Photomultiplier Tube (PMTs) sales, mainly in medical applications, such as Positron Emission Tomography and Gamma Camera imaging, increased in the US and Asia. Sales of PMTs for biological laboratory use, such as blood and cell analysis systems, also increased steadily. In addition, sales of Microfocus X-ray sources for non-destructive inspection systems increased in the domestic market. In total Electron Tube business closed the first quarter with JPY 10,398 million, up by 21.6% and operating income of JPY 4,057 million, up by 46.4% from one year previous.
(Opto-semiconductor) Sales of Silicon Photodiodes for medical application in Asia and Japan, as well as for an encoder application used in controlling industrial machines were up. In addition, sales of X-ray Image Sensors for dental instrumentation in Europe and for semiconductor inspection systems in the US increased steadily. Net sales for this business resulted in JPY 10,558 million, up by 26.5% and operating income was JPY 3,748 million, up by 100.3% from one year before.
(Imaging and Measurement Instruments) Sales of digital cameras for academic research in the field of biomedical science were up steadily in the U.S. In addition, Semiconductor Failure Analysis Systems sales in the industrial market increased mainly in Asia and Europe. However in the field of medical instruments, sales of drug screening systems grew at a sluggish pace. Net sales for this sector resulted in JPY 3,103 million, up by 41.9% from one year before and operating income was JPY 380 million (1st Quarter of FY 2010 was JPY 22 million loss).
(Others) Others sales were primarily in the semiconductor laser business and hotel operations. Net sales for the businesses were JPY 623 million, up by 52.0% and operating loss was JPY 131 million (1st Quarter of FY 2010 was JPY 172 million loss).

[R-BgO]

weiter solide: http://www.hamamatsu.com/ir/financial/result/common/pdf/fr20…

[R-BgO]

Antwort auf Beitrag Nr.: 43.215.724 von R-BgO am 27.05.12 14:39:05

habe mir nun mal eine erste Position gegönnt

[R-BgO]

Zahlen sind da: http://www.hamamatsu.com/resources/pdf/ir/fr2013-year.pdf

[R-BgO]

2014er-Zahlen sind da: http://www.hamamatsu.com/resources/pdf/ir/fr2014-year.pdf

[R-BgO]

'15er-Zahlen waren auch ok;

Nettogewinn rund 10% rauf, 11% EK-Rendite

Ein Drittel der Bilanzsumme in cash.

MedTech-Anteil rund 40%

[R-BgO]

Antwort auf Beitrag Nr.: 51.548.127 von R-BgO am 21.01.16 14:05:16

für '16

rund 10% Gewinnrückgang

[R-BgO]

[R-BgO]

auch 2017/18 dürfte wieder gut geworden sein, rund 10-15% rauf

[R-BgO]

Antwort auf Beitrag Nr.: 58.884.249 von R-BgO am 06.10.18 09:04:13

es sind sogar 19% geworden...

dafür sagen sie nun für 2018/19 Stagnation vorher

[R-BgO]

nach 9M rund 5% Gewinnrückgang

[ms1992ro]

Hi Leute, weiß jemand wo man die Aktie handeln kann?